Interleukin-21 (IL-21): Tolerability and anti-tumor activity following two 5-day cycles in patients with stage IV melanoma (MM) or renal cell carcinoma (RCC).

被引：0
|
作者：
Thompson, J. A.
Curti, B. D.
Redman, B. G.
Weber, J. S.
Agarwala, S. S.
Sievers, E. L.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Providence Portland Med Ctr, Portland, OR USA
[3] Univ Michigan Hlth Syst, Ann Arbor, MI 48109 USA
[4] Univ So Calif, Los Angeles, CA 90089 USA
[5] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15260 USA
[6] ZymoGenet Inc, Seattle, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：101S / 101S
页数：1
相关论文
共 8 条
  • [1] Preliminary tolerability and anti-tumor activity of intravenous recombinant human Interleukin-21 (IL-21) in patients with metastatic melanoma and metastatic renal cell carcinoma.
    Curti, BD
    Redman, BG
    Thompson, JA
    Sievers, EL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 166S - 166S
  • [2] Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM)
    Petrella, T. M.
    Tozer, R.
    Belanger, K.
    Savage, K. J.
    Wong, R.
    Kamel-Reid, S.
    Tron, V.
    Chen, B.
    Hunder, N. N.
    Eisenhauer, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Identification of a well-tolerated outpatient regimen of interleukin-21 (IL-21) in patients with metastatic melanoma and renal cell carcinoma (RCC)
    Thompson, JA
    Curti, BD
    Redman, BG
    Sievers, EL
    JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) : 641 - 642
  • [4] Recombinant human Interleukin-21 (rIL-21), a new cytokine for immunotherapy: results of two phase I studies in patients with metastatic melanoma (MM) or renal cell carcinoma (RCC)
    Davis, I. D.
    Redman, B. G.
    McArthur, G.
    Curti, B. D.
    Cebon, J.
    Skrumsager, B. K.
    Sievers, E. L.
    Miller, D. M.
    Kristjansen, P. E. G.
    Thompson, J. A.
    EJC SUPPLEMENTS, 2006, 4 (12): : 84 - 85
  • [5] Anti-tumor activity of recombinant human Interleukin-21 (rIL-21): Preliminary data from a phase 2a study in patients with stage IV malignant melanoma (MM) without prior treatment
    Davis, I. D.
    Brady, B.
    Millward, M.
    Skrumsager, B. K.
    Mouritzen, U.
    Kristjansen, P. E.
    McArthur, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Subcutaneous (SC) dosing of recombinant human interleukin-21 (rIL-21) is safe and has clinical activity: Results from a dose-escalation study in stage 4 melanoma (MM) or renal cell cancer (RCC)
    Schmidt, H.
    Selby, P.
    Mouritzen, U.
    Thelin, U. H.
    Kristjansen, P. E.
    Geertsen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Phase 1 study of recombinant human Interleukin-21 (rIL-211) in combination with sunitinib in patients with stage IV renal cell carcinoma
    Grunwald, V.
    Desar, I.
    Haanen, J.
    Fiedler, W.
    Olsen, M. B.
    van Herpen, C. M. L.
    EJC SUPPLEMENTS, 2008, 6 (12): : 128 - 128
  • [8] Activity of recombinant human interleukin-21 (rIL-21) in patients (pts) with stage IV malignant melanoma (MM) without prior treatment: Clinical data from a phase IIa study
    Davis, I. D.
    Brady, B.
    Kefford, R.
    Millward, M. J.
    Skrumsager, B. K.
    Mouritzen, U.
    Kristjansen, P. E.
    McArthur, G. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
1